» Articles » PMID: 33116512

Bone-Targeted Extracellular Vesicles from Mesenchymal Stem Cells for Osteoporosis Therapy

Overview
Publisher Dove Medical Press
Specialty Biotechnology
Date 2020 Oct 29
PMID 33116512
Citations 35
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Current drugs used for osteoporosis therapy show strong adverse effects. Stem cell-derived extracellular vesicles (EVs) provide another choice for osteoporosis therapy. Mouse mesenchymal stem cells (mMSCs)-derived EVs promote bone regeneration; however, their clinical application is limited due to non-specific tissue targeting. Alendronate specifically targets bone tissue via hydroxyapatite. Therefore, EVs were combined with alendronate to generate Ale-EVs by "click chemistry" to facilitate EVs targeting bone via alendronate/hydroxyapatite binding.

Methods: Ale-EVs were characterized based on size using dynamic light scattering analysis and morphology was visualized by transmission electron microscopy. Hydroxyapatite affinity of Ale-EVs was detected by flow cytometry. Bone targeting of Ale-EVs was tested by ex vivo fluorescent imaging. Cell viability was assessed by using WST-8 reduction assay kit for testing the ability of Ale-EVs to promote mMSCs proliferation. Alkaline phosphatase experiment was used to detect ability of Ale-EVs to promote differentiation of mouse mesenchymal stem cells in vitro. Western blotting and Q-PCR assay were used to detect the early marker of osteogenic differentiation. Antiosteoporotic effects of Ale-EVs were detected in ovariectomy (OVX)-induced osteoporosis rat model. The safety of the Ale-EVs in vivo was measured by H&E staining and serum markers assay.

Results: In vitro, Ale-EVs had high affinity with hydroxyapatite. Also, ex vivo data indicated that Ale-EVs-DiD treatment of mice induced strong fluorescece in bone tissues compared with EVs-DiD group. Furthermore, results suggested that Ale-EVs promoted the growth and differentiation of mouse MSCs. They also protected against osteoporosis in ovariectomy (OVX)-induced osteoporotic rats. Ale-EVs were well tolerated and no side effects were found, indicating that Ale-EVs specifically target bone and can be used as a new therapeutic in osteoporosis treatment.

Conclusion: We used the Ale-N3 to modify mouse mesenchymal stem cells-derived extracellular vesicles by copper-free "click chemistry" to generate a Ale-EVs system. The Ale-EVs had a high affinity for bone and have great potential for clinical applications in osteoporosis therapy with low systemic toxicity.

Citing Articles

SFRP1-Silencing GapmeR-Loaded Lipid-Polymer Hybrid Nanoparticles for Bone Regeneration in Osteoporosis: Effect of Dosing and Targeting Strategy.

Briffault E, Reyes R, Garcia-Garcia P, Rouco H, Diaz-Gomez L, Arnau M Int J Nanomedicine. 2024; 19:12171-12188.

PMID: 39588258 PMC: 11586229. DOI: 10.2147/IJN.S476546.


Bone-targeting engineered milk-derived extracellular vesicles for MRI-assisted therapy of osteoporosis.

Huang Q, Jiang Y, Cao Y, Ding Y, Cai J, Yang T Regen Biomater. 2024; 11:rbae112.

PMID: 39323741 PMC: 11422186. DOI: 10.1093/rb/rbae112.


Harnessing exosomes for targeted therapy: strategy and application.

Ren X, Xu R, Xu C, Su J Biomater Transl. 2024; 5(1):46-58.

PMID: 39220669 PMC: 11362351. DOI: 10.12336/biomatertransl.2024.01.005.


Potential Targeting Mechanisms for Bone-Directed Therapies.

Celik B, Leal A, Tomatsu S Int J Mol Sci. 2024; 25(15).

PMID: 39125906 PMC: 11312506. DOI: 10.3390/ijms25158339.


Rhizoma Drynariae-derived nanovesicles reverse osteoporosis by potentiating osteogenic differentiation of human bone marrow mesenchymal stem cells targeting ER signaling.

Zhao Q, Feng J, Liu F, Liang Q, Xie M, Dong J Acta Pharm Sin B. 2024; 14(5):2210-2227.

PMID: 38799625 PMC: 11119514. DOI: 10.1016/j.apsb.2024.02.005.


References
1.
Thery C, Zitvogel L, Amigorena S . Exosomes: composition, biogenesis and function. Nat Rev Immunol. 2002; 2(8):569-79. DOI: 10.1038/nri855. View

2.
Villasante A, Marturano-Kruik A, Ambati S, Liu Z, Godier-Furnemont A, Parsa H . Recapitulating the Size and Cargo of Tumor Exosomes in a Tissue-Engineered Model. Theranostics. 2016; 6(8):1119-30. PMC: 4893640. DOI: 10.7150/thno.13944. View

3.
Diaz-Borjon A, Seyler T, Chen N, Lim S . Bisphosphonate-associated arthritis. J Clin Rheumatol. 2006; 12(3):131-3. DOI: 10.1097/01.rhu.0000221796.06383.4e. View

4.
Kacprzak K, Skiera I, Piasecka M, Paryzek Z . Alkaloids and Isoprenoids Modification by Copper(I)-Catalyzed Huisgen 1,3-Dipolar Cycloaddition (Click Chemistry): Toward New Functions and Molecular Architectures. Chem Rev. 2016; 116(10):5689-743. DOI: 10.1021/acs.chemrev.5b00302. View

5.
Khan M, Cheung A, Khan A . Drug-Related Adverse Events of Osteoporosis Therapy. Endocrinol Metab Clin North Am. 2017; 46(1):181-192. DOI: 10.1016/j.ecl.2016.09.009. View